Neuroepithelial Stem Cells: The many roles of C1q

The ability of C1q to bind to a variety of receptors has implications for signaling biology, spinal cord injury and, possibly, the evolution of the complement system.
  1. Mark Noble  Is a corresponding author
  2. Christoph Pröschel
  1. Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, United States

The protein C1q is best known for its role in the immune system: as a part of the C1 complex of the complement cascade, it helps to clear microbes and cellular debris from the body. However, it also has other roles beyond the immune system: for example, working with other elements of the complement cascade it helps to eliminate immature synapses during development of the visual system (Stevens et al., 2007) and is involved in Wnt signaling in muscle cells (Naito et al., 2012). C1q can also bind to myelin-associated glycoprotein and mask its ability to inhibit neurite outgrowth (Peterson et al., 2015), while the loss of C1q in mice results in cognitive decline (Stephan et al., 2013). More recent studies suggest a role for C1q in neurodegeneration (reviewed in Cho, 2019).

Now, in eLife, Francisca Benavente (University of California Irvine and Universidad del Desarrollo), Aileen Anderson (UC Irvine) and colleagues report new roles for C1q that have intriguing implications for signaling biology, recovery from spinal cord injury, stem cell-based therapies and, possibly, the evolution of the complement system (Benavente et al., 2020). The work shows that C1q is a ligand that can bind directly to several previously unidentified receptors (CD44, GPR62, BAI1, c-MET, and ADCY5), triggering the activation of downstream signaling pathways. The researchers demonstrate that in doing so, C1q can modulate different aspects of the biology of neuroepithelial stem cells (NSCs). Specifically, they show that C1q promotes the migration of NSCs by binding to a cell-surface glycoprotein called CD44, while promoting NSC proliferation via interactions with G-protein coupled receptor signaling pathways.

CD44 knockout eliminates the ability of C1q to promote chemotaxis, but not the ability to promote division, in NSCs. Likewise, the effects of C1q on NSC differentiation appear to be independent of signaling via CD44. Nonetheless, C1q also exhibited a dose-dependent effect on NSC differentiation: while a low nM dose significantly increased the generation of Olig-2+ oligodendrocyte-lineage cells in wild-type NSCs, fewer Olig-2+ cells were seen with higher concentrations of C1q in both wild-type and CD44 knock-out cells. A similar inhibitory effect was observed on the differentiation of two other cell types (GFAP+ astroglia and ßIII-tubulin expressing neuronal lineage cells), which also appeared to be independent of signaling via CD44.

Benavente et al. also demonstrate that C1q, again acting via CD44, has important effects on the ability of transplanted NSCs to promote recovery from spinal cord injury. Previously they had shown that delayed transplantation into a rodent model of spinal cord injury was associated with the migration of cells away from the injury epicenter, differentiation of the NSCs mostly into oligodendrocytes, and improved motor function (Salazar et al., 2010; Hooshmand et al., 2017). In contrast, transplantation right after the injury was associated with increased migration towards the epicenter, differentiation mostly into astroglial cells, and no effects on motor recovery. Now, they have found that the genetic inhibition of CD44 in NSCs, or the use of antibodies to inhibit C1q, prevented clustering of transplanted NSCs in the injury epicenter, reduced astroglial differentiation, and significantly improved motor outcomes when NSCs were transplanted into mice immediately after injury. They also found elevated levels of C1q in the injury epicenter following spinal cord injury, which suggests that this pathway has a role in the response to the injury.

The latest work also raises a number of interesting questions. Would inhibiting inflammation increase the utility of NSC transplantation in spinal cord injury? Does the efficacy of delayed transplantation depend upon decreased inflammation and C1q production in the injury site by this time? Moreover, the binding of C1q to other NSC receptor proteins (including two G-protein coupled receptors and the receptor tyrosine kinase c-Met) suggests that C1q may modulate a complex array of effects on NSC behavior within the injury site.

One would also like to know if the latest results are relevant to recovery in areas of the central nervous system where NSCs still exist in adults, and whether there are effects of age-related increases in C1q on these NSC compartments. Moreover, CD44 is expressed in many different cell types, and its expression changes dramatically during injury: are other cells susceptible to C1q-mediated effects on chemotaxis via CD44? Also, if the normal expression of C1q in an injury site is to promote the migration of cells that might be important in repair, would decreasing the inflammatory response be counterproductive in some instances? It would also be interesting to explore the effects of C1q on cell function more generally.

The observations that C1q is a ligand for multiple receptors may also lead to a better understanding of the evolution of the complement system. The evolutionary value of a single protein that works as a component of a multi-protein complex is difficult to discern. However, if C1q started off as a signaling ligand, its evolution is easier to understand. In addition, one wonders whether other components of the complement cascade might also have additional roles outside of their immunological functions.

Regardless of the answers to these questions, the discovery that C1q is itself a ligand for multiple receptors, and is capable of modulating important NSC functions, opens up a new window for studying the biology of C1q that is sure to lead to a series of provocative further discoveries.

References

Article and author information

Author details

  1. Mark Noble

    Mark Noble is in the Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, United States

    For correspondence
    mark_noble@urmc.rochester.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2375-7773
  2. Christoph Pröschel

    Christoph Pröschel is in the Department of Biomedical Genetics, University of Rochester School of Medicine and Dentistry, Rochester, United States

    Competing interests
    No competing interests declared

Publication history

  1. Version of Record published: September 14, 2020 (version 1)

Copyright

© 2020, Noble and Pröschel

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,003
    views
  • 108
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mark Noble
  2. Christoph Pröschel
(2020)
Neuroepithelial Stem Cells: The many roles of C1q
eLife 9:e61599.
https://doi.org/10.7554/eLife.61599
  1. Further reading

Further reading

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine
    Nikola Sekulovski, Jenna C Wettstein ... Kenichiro Taniguchi
    Research Article

    Amniogenesis, a process critical for continuation of healthy pregnancy, is triggered in a collection of pluripotent epiblast cells as the human embryo implants. Previous studies have established that bone morphogenetic protein (BMP) signaling is a major driver of this lineage specifying process, but the downstream BMP-dependent transcriptional networks that lead to successful amniogenesis remain to be identified. This is, in part, due to the current lack of a robust and reproducible model system that enables mechanistic investigations exclusively into amniogenesis. Here, we developed an improved model of early amnion specification, using a human pluripotent stem cell-based platform in which the activation of BMP signaling is controlled and synchronous. Uniform amniogenesis is seen within 48 hr after BMP activation, and the resulting cells share transcriptomic characteristics with amnion cells of a gastrulating human embryo. Using detailed time-course transcriptomic analyses, we established a previously uncharacterized BMP-dependent amniotic transcriptional cascade, and identified markers that represent five distinct stages of amnion fate specification; the expression of selected markers was validated in early post-implantation macaque embryos. Moreover, a cohort of factors that could potentially control specific stages of amniogenesis was identified, including the transcription factor TFAP2A. Functionally, we determined that, once amniogenesis is triggered by the BMP pathway, TFAP2A controls the progression of amniogenesis. This work presents a temporally resolved transcriptomic resource for several previously uncharacterized amniogenesis states and demonstrates a critical intermediate role for TFAP2A during amnion fate specification.

    1. Stem Cells and Regenerative Medicine
    Sarah Duchamp de Chastaigne, Catherine M Sawai
    Insight

    A new mathematical model can estimate the number of precursor cells that contribute to regenerating blood cells in mice.